KIORA PHARMACEUTICALS, INC.: nonoperating income or expense

What this measure means

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Exact concept: us-gaap:NonoperatingIncomeExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• KIORA PHARMACEUTICALS, INC.: total assets
• KIORA PHARMACEUTICALS, INC.: total liabilities
• KIORA PHARMACEUTICALS, INC.: stockholders equity
• KIORA PHARMACEUTICALS, INC.: cash and cash equivalents
• KIORA PHARMACEUTICALS, INC.: net income or loss
• KIORA PHARMACEUTICALS, INC.: operating cash flow
• KIORA PHARMACEUTICALS, INC.: capital expenditure payments
• KIORA PHARMACEUTICALS, INC.: revenue
• KIORA PHARMACEUTICALS, INC.: contract revenue excluding tax
• KIORA PHARMACEUTICALS, INC.: financing cash flow
• KIORA PHARMACEUTICALS, INC.: investing cash flow
• KIORA PHARMACEUTICALS, INC.: retained earnings or deficit
• KIORA PHARMACEUTICALS, INC.: basic weighted-average shares
• KIORA PHARMACEUTICALS, INC.: diluted weighted-average shares
• KIORA PHARMACEUTICALS, INC.: basic earnings per share
• KIORA PHARMACEUTICALS, INC.: diluted earnings per share
• KIORA PHARMACEUTICALS, INC.: income tax expense or benefit
• KIORA PHARMACEUTICALS, INC.: net property, plant and equipment
• KIORA PHARMACEUTICALS, INC.: share-based compensation expense
• KIORA PHARMACEUTICALS, INC.: operating income or loss
• KIORA PHARMACEUTICALS, INC.: current assets
• KIORA PHARMACEUTICALS, INC.: interest expense
• KIORA PHARMACEUTICALS, INC.: current liabilities
• KIORA PHARMACEUTICALS, INC.: current accounts payable
• KIORA PHARMACEUTICALS, INC.: goodwill carrying amount
• KIORA PHARMACEUTICALS, INC.: net finite-lived intangible assets
• KIORA PHARMACEUTICALS, INC.: net current accounts receivable
• KIORA PHARMACEUTICALS, INC.: operating expenses
• KIORA PHARMACEUTICALS, INC.: research and development expense
• KIORA PHARMACEUTICALS, INC.: common shares outstanding
• KIORA PHARMACEUTICALS, INC.: cash including restricted cash
• KIORA PHARMACEUTICALS, INC.: additional paid-in capital
• KIORA PHARMACEUTICALS, INC.: accumulated other comprehensive income or loss
• KIORA PHARMACEUTICALS, INC.: total equity including noncontrolling interests
• KIORA PHARMACEUTICALS, INC.: operating lease right-of-use asset
• KIORA PHARMACEUTICALS, INC.: operating lease liability
• KIORA PHARMACEUTICALS, INC.: gross property, plant and equipment
• KIORA PHARMACEUTICALS, INC.: accumulated depreciation on property, plant and equipment
• KIORA PHARMACEUTICALS, INC.: net intangible assets excluding goodwill
• KIORA PHARMACEUTICALS, INC.: other noncurrent assets
• KIORA PHARMACEUTICALS, INC.: accrued current liabilities
• KIORA PHARMACEUTICALS, INC.: prepaid expenses and other current assets
• KIORA PHARMACEUTICALS, INC.: net deferred tax assets
• KIORA PHARMACEUTICALS, INC.: net deferred tax liabilities
• KIORA PHARMACEUTICALS, INC.: pre-tax income or loss from continuing operations
• KIORA PHARMACEUTICALS, INC.: profit or loss including noncontrolling interests
• KIORA PHARMACEUTICALS, INC.: comprehensive income or loss
• KIORA PHARMACEUTICALS, INC.: net income available to common stockholders
• KIORA PHARMACEUTICALS, INC.: general and administrative expense
• KIORA PHARMACEUTICALS, INC.: depreciation expense
• KIORA PHARMACEUTICALS, INC.: depreciation, depletion and amortization
• KIORA PHARMACEUTICALS, INC.: amortization of intangible assets
• KIORA PHARMACEUTICALS, INC.: nonoperating interest expense
• KIORA PHARMACEUTICALS, INC.: other nonoperating income or expense
• KIORA PHARMACEUTICALS, INC.: current income tax expense or benefit
• KIORA PHARMACEUTICALS, INC.: deferred income tax expense or benefit
• KIORA PHARMACEUTICALS, INC.: proceeds from issuing common stock
• KIORA PHARMACEUTICALS, INC.: change in accounts receivable
• KIORA PHARMACEUTICALS, INC.: change in accounts payable

Inspect the source

Entity

KIORA PHARMACEUTICALS, INC. / CIK 0001372514

Captured

2026-09-20T07:57:09.611Z

SEC response SHA-256

3c8ad9197d1b760a7f418642919ba51ce1343d392d1a4d1fce0d72996117d019

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001372514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))